BioCryst Pharmaceuticals, Inc. and Astria Therapeutics, Inc. have entered into a definitive agreement under which BioCryst will acquire all outstanding shares of Astria. The consideration for each Astria share will consist of $8.55 in cash and 0.59 shares of BioCryst common stock. The transaction has received unanimous approval from the boards of both companies and is expected to close in the first quarter of 2026, subject to customary closing conditions and Astria stockholder approval. Upon completion, Astria CEO Jill C. Milne will join the BioCryst Board of Directors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112064626) on November 12, 2025, and is solely responsible for the information contained therein.